SCHEMBL5202992

SCHEMBL5202992

COC(=O)C1CCC(c2nc(-c3cccc(C(F)(F)F)c3)c[nH]2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
KDM1A O60341 6/20 0.44
MAOB P27338 4/20 0.44
MAOA P21397 3/20 0.44
JAK2 O60674 1/20 0.42
PIN1 Q13526 1/20 0.41
SYK P43405 2/20 0.41
VCP P55072 1/20 0.41
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CG P48736 1/20 0.40
KMO O15229 1/20 0.40
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
RPS6KA3 P51812 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5203000 1.00 KCNH2 (0.46) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL14608992 0.87 KCNH2 (0.47) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL5206565 0.87 KCNH2 (0.47) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL5205158 0.87 KCNH2 (0.47) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL5207210 0.86 KDM1A (0.55) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL440195 0.84 TDP1 (0.43) VCP
SCHEMBL407689 0.84 TDP1 (0.43) VCP
SCHEMBL5207199 0.82 KCNH2 (0.51) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL5209708 0.82 KCNH2 (0.44) KCNH2KDM1AMAOBMAOAJAK2
SCHEMBL5207443 0.81 ALDH1A1 (0.48) KCNH2KDM1AMAOBMAOAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R KCNH2 1937/4885KDM1A 783/4885MAOB 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.